{"id":"h3n2","rwe":[{"pmid":"41911534","year":"2026","title":"Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection.","finding":"","journal":"ACS nano","studyType":"Clinical Study"},{"pmid":"41909675","year":"2026","title":"Increased levels of α2-3- and α2-6-linked sialic acids during airway inflammation govern influenza A binding to peripheral airway mucins in a subtype-dependent manner.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41905250","year":"2026","title":"Epidemiology of influenza A and B viruses in Mauritius over an 8-year period, 2009-2016.","finding":"","journal":"Virology","studyType":"Clinical Study"},{"pmid":"41902235","year":"2026","title":"A CNN-Based Model of Cross-Immunity to Influenza A(H3N2) Virus: Testing Under \"Real-World\" Conditions.","finding":"","journal":"Viruses","studyType":"Clinical Study"},{"pmid":"41898859","year":"2026","title":"Gene Expression Profiles of Inflammatory Mediators in Influenza A and B Virus Infections: Insights from Riyadh, Saudi Arabia (2020-2023).","finding":"","journal":"Genes","studyType":"Clinical Study"}],"_fda":{"id":"0590e5fd-6217-b75a-e063-6294a90acb86","set_id":"0590e5fd-6216-b75a-e063-6294a90acb86","openfda":{"unii":["GRN94TP8YV","AU5C98U4BB","CQV855H5FG","9HB0XUS9TM"],"route":["ORAL"],"spl_id":["0590e5fd-6217-b75a-e063-6294a90acb86"],"brand_name":["INFLUENZINUM"],"spl_set_id":["0590e5fd-6216-b75a-e063-6294a90acb86"],"package_ndc":["0220-5085-41"],"product_ndc":["0220-5085"],"generic_name":["INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED),INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)"],"product_type":["HUMAN OTC DRUG"],"substance_name":["INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)","INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED)","INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)","INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)"],"manufacturer_name":["Boiron"],"is_original_packager":[true]},"purpose":[""],"version":"1","stop_use":["Stop use and ask a doctor if symptoms persist for more than 3 days or worsen."],"warnings":[""],"questions":["1-800-BOIRON-1 (1-800-264-7661), BoironUSA.com Info@Boiron.com Distributed by Boiron, Inc. Newtown Square, PA 19073"],"effective_time":"20230917","active_ingredient":["Active ingredient** Influenzinum 12C HPUS See product name on front panel (contains 0.443 mg of the active ingredient per pellet)"],"inactive_ingredient":["lactose, sucrose"],"indications_and_usage":["Relieves after effects of flu or flu-like symptoms * See symptoms on front panel."],"spl_unclassified_section":["Do not use if pellet dispenser seal is broken. Contains approx 80 pellets. How to dispense pellets? Turn tube upside down. Twist until 5 pellets are dispensed into cap. Carefully remove the cap and use it to pour pellets under the tongue. *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE NOT ACCEPTED MEDICAL EVIDENCE. NOT FDA EVALUATED. **C,K,CK, and X are homeopathic dilutions: see BoironUSA.com/info for details. The letters \"HPUS\" indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States."],"dosage_and_administration":["Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor."],"spl_product_data_elements":["INFLUENZINUM INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED),INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) LACTOSE, UNSPECIFIED FORM INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) SUCROSE"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use"],"keep_out_of_reach_of_children":["Keep out of reach of children."],"package_label_principal_display_panel":["label"]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"Active","category":"status"},{"label":"flu-like symptoms","category":"indication"},{"label":"Boiron","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"ANGIOEDEMA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"AORTIC DILATATION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BLOOD PRESSURE INCREASED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"CEREBROVASCULAR ACCIDENT","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"CONTUSION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"DYSPHAGIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"DYSPHONIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"EYELID OEDEMA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"FACE OEDEMA","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[{"effect":"Pain (injection-site)","drugRate":"50%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"30%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"30%","severity":"common","organSystem":""},{"effect":"Redness (injection-site)","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"10%","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Boiron","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=H3N2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:08:21.768081+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/H3N2","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:08:28.629059+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:08:27.185890+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=H3N2","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:08:27.609908+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:08:20.401674+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:08:20.401705+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:08:29.043939+00:00"}},"allNames":"influenzinum","offLabel":[],"synonyms":["Influenzinum","INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)"],"timeline":[],"approvals":[],"brandName":"Influenzinum","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Influenzinum (H3N2) is a highly diluted solution of the H3N2 influenza virus, which is thought to stimulate the body's natural defenses through a process known as 'hormesis', where a small dose of a substance can have a beneficial effect on the body."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H3N2","title":"Influenza A virus subtype H3N2","extract":"Influenza A virus subtype H3N2 (A/H3N2) is a subtype of influenza A virus (IAV). Some human-adapted strains of A/H3N2 are endemic in humans and are one cause of seasonal influenza (flu). Other strains of A/H3N2 are endemic in pigs and in birds. Subtypes of IAV are defined by the combination of the antigenic H and N proteins in the viral envelope; for example, \"H1N1\" designates an IAV subtype that has a type-1 hemagglutinin (H) protein and a type-1 neuraminidase (N) protein."},"commercial":{},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"H3N2\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=h3n2","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=h3n2","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H3N2","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:24:10.330407","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:30.400324+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"h3n2","indications":{"approved":[{"name":"flu-like symptoms","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":["Influenza, Human"],"enrollment":35800,"completionDate":"2026-12"},{"nctId":"NCT05332899","phase":"PHASE1","title":"Influenza Human Challenge Model","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-05-24","conditions":["Influenza"],"enrollment":80,"completionDate":"2027-12"},{"nctId":"NCT06753474","phase":"PHASE1","title":"A/Texas Flu Challenge","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-02-04","conditions":["Influenza"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":["Influenza"],"enrollment":1200,"completionDate":"2026-09-30"},{"nctId":"NCT07302256","phase":"PHASE1","title":"A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-16","conditions":["Influenza"],"enrollment":120,"completionDate":"2026-08-31"},{"nctId":"NCT07305207","phase":"PHASE1","title":"Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness","status":"NOT_YET_RECRUITING","sponsor":"Dalhousie University","startDate":"2026-02-01","conditions":["Influenza (Healthy Volunteers)"],"enrollment":32,"completionDate":"2028-01-31"},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":["Influenza"],"enrollment":366,"completionDate":"2024-07-09"},{"nctId":"NCT04978454","phase":"PHASE1","title":"Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":["Influenza"],"enrollment":60,"completionDate":"2022-09-22"},{"nctId":"NCT06613737","phase":"NA","title":"Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain","status":"COMPLETED","sponsor":"Hvivo","startDate":"2024-09-11","conditions":["Influenza A H3N2"],"enrollment":33,"completionDate":"2025-03-10"},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":["Seasonal Influenza"],"enrollment":3300,"completionDate":"2024-05-23"},{"nctId":"NCT04960397","phase":"PHASE1","title":"Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-10","conditions":["H3N2 Influenza"],"enrollment":140,"completionDate":"2024-04-12"},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":["COVID-19"],"enrollment":9320,"completionDate":"2026-09-30"},{"nctId":"NCT07063849","phase":"PHASE1","title":"Pilot Influenza Challenge Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daniel Hoft, MD, PhD","startDate":"2025-05-20","conditions":["Influenza"],"enrollment":12,"completionDate":"2026-06-30"},{"nctId":"NCT06972810","phase":"NA","title":"Human Infection Study of H3N2 Influenza in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2025-05-05","conditions":["Influenza"],"enrollment":12,"completionDate":"2026-06-30"},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":["Varicella","Influenza Vaccine"],"enrollment":899,"completionDate":"2024-11-15"},{"nctId":"NCT06620185","phase":"NA","title":"GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2025-04-16","conditions":["Influenza"],"enrollment":36,"completionDate":"2026-01-06"},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":["Influenza, Human"],"enrollment":7741,"completionDate":"2025-01-30"},{"nctId":"NCT06485752","phase":"PHASE2,PHASE3","title":"Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine","status":"WITHDRAWN","sponsor":"Novavax","startDate":"2024-11","conditions":["COVID-19"],"enrollment":0,"completionDate":"2025-02-04"},{"nctId":"NCT06476275","phase":"PHASE1","title":"Single Dose Texas 2017 (H3N2) Challenge Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-11","conditions":["Influenza Viral Infections"],"enrollment":33,"completionDate":"2025-02-10"},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":["Influenza, Human","Influenza, Human Prevention","Influenza a","Influenza B","Influenza Viral Infections"],"enrollment":4400,"completionDate":"2025-10-15"},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":["Influenza, Human","Influenza a","Influenza Type B","Influenza Viral Infections"],"enrollment":180,"completionDate":"2025-07-31"},{"nctId":"NCT02755948","phase":"NA","title":"Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-04","conditions":["Respiratory Syncytial Virus Infections","Influenza, Human"],"enrollment":75,"completionDate":"2020-02-01"},{"nctId":"NCT03849560","phase":"PHASE2,PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":["Influenza"],"enrollment":612,"completionDate":"2017-08"},{"nctId":"NCT01056185","phase":"","title":"Respiratory Virus Hospitalization Study (FLU 003 Plus)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-08","conditions":["Influenza","Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)","Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)"],"enrollment":1000,"completionDate":"2024-08-30"},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":["Influenza"],"enrollment":839,"completionDate":"2022-03-03"},{"nctId":"NCT05895955","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":["Influenza"],"enrollment":290,"completionDate":"2025-07-31"},{"nctId":"NCT05245552","phase":"PHASE3","title":"A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-08-08","conditions":["Seasonal Influenza"],"enrollment":217,"completionDate":"2023-08-04"},{"nctId":"NCT05696067","phase":"PHASE1,PHASE2","title":"Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2022-09-13","conditions":["COVID-19"],"enrollment":200,"completionDate":"2023-05-31"},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":["Influenza","Human"],"enrollment":471,"completionDate":"2021-05-24"},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":["Influenza, Human"],"enrollment":1056,"completionDate":"2023-03-31"},{"nctId":"NCT03315104","phase":"PHASE2","title":"Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2017-11-17","conditions":["Influenza A H3N2","Influenza A H1N1"],"enrollment":65,"completionDate":"2019-06-17"},{"nctId":"NCT06280144","phase":"PHASE4","title":"Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-09-22","conditions":["Influenza Prevention"],"enrollment":6080,"completionDate":"2024-10-30"},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":["Influenza"],"enrollment":632,"completionDate":"2020-03-30"},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":["Prevention of Influenza"],"enrollment":2550,"completionDate":"2024-01-05"},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":["Influenza"],"enrollment":1980,"completionDate":"2021-09-14"},{"nctId":"NCT05512494","phase":"PHASE4","title":"Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-11-27","conditions":["Seasonal Influenza"],"enrollment":1260,"completionDate":"2023-01-24"},{"nctId":"NCT04204993","phase":"NA","title":"Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2020-02-11","conditions":["Influenza A H3N2"],"enrollment":20,"completionDate":"2021-05-17"},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":["Influenza, Human"],"enrollment":380,"completionDate":"2022-08-05"},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":["Influenza"],"enrollment":864,"completionDate":"2022-04-01"},{"nctId":"NCT04785794","phase":"PHASE1","title":"Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old","status":"COMPLETED","sponsor":"FluGen Inc","startDate":"2021-06-30","conditions":["Influenza Vaccine"],"enrollment":122,"completionDate":"2021-11-30"},{"nctId":"NCT05163847","phase":"PHASE1","title":"Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults","status":"COMPLETED","sponsor":"FluGen Inc","startDate":"2022-06-14","conditions":["Influenza Vaccine"],"enrollment":303,"completionDate":"2022-11-03"},{"nctId":"NCT03438487","phase":"","title":"Flucelvax (TIVc or QIVc) Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-01","conditions":["Influenza, Human","Pregnancy","Birth Defect"],"enrollment":692,"completionDate":"2020-12-31"},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":["Influenza"],"enrollment":120,"completionDate":"2022-06-16"},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":["Influenza"],"enrollment":816,"completionDate":"2023-12-31"},{"nctId":"NCT04523090","phase":"PHASE2,PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":["COVID-19"],"enrollment":322,"completionDate":"2022-08-12"},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":["Influenza","Vaccines"],"enrollment":1600,"completionDate":"2023-07-31"},{"nctId":"NCT03686514","phase":"PHASE4","title":"The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics","status":"TERMINATED","sponsor":"Emory University","startDate":"2018-10-22","conditions":["Influenza"],"enrollment":39,"completionDate":"2020-06-20"},{"nctId":"NCT05389137","phase":"PHASE4","title":"To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years","status":"UNKNOWN","sponsor":"Wuhan Institute of Biological Products Co., Ltd","startDate":"2022-03-02","conditions":["Influenza"],"enrollment":360,"completionDate":"2022-10"},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":["COVID-19"],"enrollment":120,"completionDate":"2022-03-04"},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":["Influenza"],"enrollment":4648,"completionDate":"2008-05-28"},{"nctId":"NCT03999554","phase":"PHASE1","title":"Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines","status":"COMPLETED","sponsor":"FluGen Inc","startDate":"2019-09-03","conditions":["Influenza A"],"enrollment":206,"completionDate":"2020-07-01"},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":["Influenza","Influenza Immunisation"],"enrollment":43,"completionDate":"2020-08-27"},{"nctId":"NCT04984408","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-10-01","conditions":["COVID-19 Disease"],"enrollment":8825,"completionDate":"2024-09-30"},{"nctId":"NCT04801888","phase":"PHASE4","title":"Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-03-23","conditions":["COVID-19","Influenza"],"enrollment":480,"completionDate":"2021-05-28"},{"nctId":"NCT03328325","phase":"PHASE4","title":"Age and Response to Flu Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-12-14","conditions":["Influenza","Influenza Immunisation"],"enrollment":152,"completionDate":"2020-04-20"},{"nctId":"NCT03883113","phase":"PHASE2","title":"Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-06-03","conditions":["Influenza"],"enrollment":145,"completionDate":"2020-04-17"},{"nctId":"NCT00283283","phase":"PHASE2","title":"Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-11","conditions":["Influenza"],"enrollment":1316,"completionDate":"2006-05"},{"nctId":"NCT04530786","phase":"","title":"Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-12","conditions":["Influenza"],"enrollment":100,"completionDate":"2009-07"},{"nctId":"NCT04531787","phase":"","title":"Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-08","conditions":["Influenza"],"enrollment":139,"completionDate":"2009-07"},{"nctId":"NCT04533139","phase":"","title":"Influenza Vaccine in Lung Transplant Patients - Antibody","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-12","conditions":["Influenza"],"enrollment":122,"completionDate":"2009-07"},{"nctId":"NCT04531657","phase":"","title":"Influenza Vaccine in Lung Transplant Patients - Seroprotection","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-12","conditions":["Influenza"],"enrollment":79,"completionDate":"2009-07"},{"nctId":"NCT04533061","phase":"","title":"Influenza Vaccine in Lung Transplant Patients - T Cells","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-12","conditions":["Influenza"],"enrollment":24,"completionDate":"2009-07"},{"nctId":"NCT02822105","phase":"PHASE1","title":"Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"FluGen Inc","startDate":"2016-06","conditions":["Flu"],"enrollment":96,"completionDate":"2017-11"},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":["Avian Influenza","Influenza","Influenza Immunisation"],"enrollment":149,"completionDate":"2019-07-25"},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":["Influenza"],"enrollment":1503,"completionDate":"2015-05"},{"nctId":"NCT04372719","phase":"PHASE1","title":"A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers","status":"COMPLETED","sponsor":"SGS Life Sciences, a division of SGS Belgium NV","startDate":"2016-11-02","conditions":["Influenza, Human"],"enrollment":36,"completionDate":"2016-12-28"},{"nctId":"NCT04355806","phase":"","title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-06-01","conditions":["Non Small Cell Lung Cancer","Influenza Vaccine"],"enrollment":160,"completionDate":"2023-05-31"},{"nctId":"NCT03390166","phase":"PHASE2,PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":["Influenza"],"enrollment":945,"completionDate":"2019-02-12"},{"nctId":"NCT02746783","phase":"PHASE1,PHASE2","title":"Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2013-10","conditions":["Healthy Volunteers"],"enrollment":163,"completionDate":"2015-07"},{"nctId":"NCT02894840","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":["Influenza"],"enrollment":340,"completionDate":"2016-11"},{"nctId":"NCT02525055","phase":"NA","title":"Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model","status":"COMPLETED","sponsor":"Hvivo","startDate":"2014-01","conditions":["Influenza"],"enrollment":46,"completionDate":"2014-08-11"},{"nctId":"NCT02594189","phase":"PHASE1","title":"Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-10-31","conditions":["Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2"],"enrollment":49,"completionDate":"2017-11-01"},{"nctId":"NCT03220048","phase":"PHASE2","title":"Study Examining PrEP-001 in Healthy Subjects","status":"COMPLETED","sponsor":"Hvivo","startDate":"2015-09-16","conditions":["Influenza A H3N2"],"enrollment":66,"completionDate":"2016-02"},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":["Vaccine Response Impaired","Allogeneic Stem Cell Transplantation"],"enrollment":200,"completionDate":"2017-12-31"},{"nctId":"NCT02415842","phase":"","title":"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-26","conditions":["Immunologic Tests"],"enrollment":414,"completionDate":"2018-02-16"},{"nctId":"NCT03095599","phase":"PHASE2,PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":["Influenza, Human"],"enrollment":889,"completionDate":"2017-10-05"},{"nctId":"NCT02572817","phase":"PHASE3","title":"Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11","conditions":["Influenza A Virus Infection"],"enrollment":138,"completionDate":"2018-05-18"},{"nctId":"NCT03540823","phase":"PHASE4","title":"Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-04-23","conditions":["Systemic Lupus","Sjogren's Syndrome"],"enrollment":300,"completionDate":"2018-08-23"},{"nctId":"NCT02935192","phase":"PHASE3","title":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2016-11-28","conditions":["Influenza"],"enrollment":480,"completionDate":"2017-03-25"},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":["Influenza, Human"],"enrollment":60,"completionDate":"2016-02"},{"nctId":"NCT02876159","phase":"PHASE4","title":"The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-07","conditions":["Influenza"],"enrollment":20,"completionDate":"2016-12-01"},{"nctId":"NCT03143101","phase":"PHASE4","title":"Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-08","conditions":["Influenza","Healthy"],"enrollment":200,"completionDate":"2017-09-29"},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":["Influenza","HIV","Tuberculosis"],"enrollment":301,"completionDate":"2014-11-20"},{"nctId":"NCT01356316","phase":"PHASE4","title":"Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2010-08","conditions":["Influenza"],"enrollment":120,"completionDate":"2011-03"},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":["Influenza"],"enrollment":300,"completionDate":"2016-12"},{"nctId":"NCT00952705","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":["Healthy or Stable Underlying Chronic Medical Condition"],"enrollment":1800,"completionDate":"2010-03"},{"nctId":"NCT03399357","phase":"","title":"Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2017-05-31","conditions":["Influenza Vaccine","Immune Response","Elderly","Vitamin D Deficiency","Metabolic Disease","Diabetes Mellitus"],"enrollment":240,"completionDate":"2019-02-28"},{"nctId":"NCT01215981","phase":"NA","title":"Influenza Vaccine Post Allogeneic Transplant","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-09","conditions":["Hematopoietic Stem Cell Transplant","Hematologic Malignancy"],"enrollment":68,"completionDate":"2011-06"},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":["Influenza"],"enrollment":9003,"completionDate":"2015-05"},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":["Human Influenza"],"enrollment":254648,"completionDate":"2016-09"},{"nctId":"NCT02964065","phase":"PHASE3","title":"A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2016-11","conditions":["Influenza"],"enrollment":9000,"completionDate":""},{"nctId":"NCT02909842","phase":"NA","title":"Effect of Drinking Fermented Milk on Immune Response","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-01-01","conditions":["Influenza"],"enrollment":60,"completionDate":"2017-08-01"},{"nctId":"NCT01056354","phase":"","title":"Respiratory Virus Outpatient Study (FLU 002 Plus)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-08","conditions":["Influenza and Other Novel Respiratory Viruses"],"enrollment":11719,"completionDate":"2017-05-12"},{"nctId":"NCT00112112","phase":"PHASE1","title":"Safety Study to Evaluate FluMist in Immunocompromised Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2005-08-01","conditions":["Cancer"],"enrollment":20,"completionDate":"2008-05-01"},{"nctId":"NCT00344305","phase":"PHASE2","title":"A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-05-01","conditions":["Healthy"],"enrollment":200,"completionDate":"2006-12-01"},{"nctId":"NCT02100436","phase":"PHASE2","title":"Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-06-11","conditions":["Influenza"],"enrollment":270,"completionDate":"2015-03-20"},{"nctId":"NCT01998477","phase":"PHASE3","title":"A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-10","conditions":["Influenza"],"enrollment":430,"completionDate":"2014-07"},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":["Influenza, Human"],"enrollment":3484,"completionDate":"2015-04"},{"nctId":"NCT01518478","phase":"EARLY_PHASE1","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":["Atopic Dermatitis"],"enrollment":40,"completionDate":"2012-03"},{"nctId":"NCT03028116","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-05","conditions":["Influenza, Human"],"enrollment":44,"completionDate":"2016-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"UNII":"GRN94TP8YV","SPL_ID":"0590e5fd-6217-b75a-e063-6294a90acb86"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Boiron","relationship":"Original Developer"}],"publicationCount":8948,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Boiron","recentPublications":[{"date":"2026 Mar 30","pmid":"41911534","title":"Combination mRNA Vaccine Adjuvanted with CpG Oligodeoxynucleotides Enhances Protection against Respiratory Virus Infection.","journal":"ACS nano"},{"date":"2026","pmid":"41909675","title":"Increased levels of α2-3- and α2-6-linked sialic acids during airway inflammation govern influenza A binding to peripheral airway mucins in a subtype-dependent manner.","journal":"Frontiers in immunology"},{"date":"2026 Mar 26","pmid":"41905250","title":"Epidemiology of influenza A and B viruses in Mauritius over an 8-year period, 2009-2016.","journal":"Virology"},{"date":"2026 Mar 6","pmid":"41902235","title":"A CNN-Based Model of Cross-Immunity to Influenza A(H3N2) Virus: Testing Under \"Real-World\" Conditions.","journal":"Viruses"},{"date":"2026 Mar 17","pmid":"41898859","title":"Gene Expression Profiles of Inflammatory Mediators in Influenza A and B Virus Infections: Insights from Riyadh, Saudi Arabia (2020-2023).","journal":"Genes"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Boiron","companyId":"boiron","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:30.400324+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}